In one paragraphArticle in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
41 authors.
Cinta LleixàNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-9971-0584 Elba Pascual-GoñiNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0001-7336-4305 Lorena Martín-AguilarNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-1553-2224 Marta Caballero-ÁvilaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0001-9850-8504 Roger Collet-VidiellaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0003-1668-1018 Clara Tejada-IllaNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0009-0008-2856-7179 Paula LlarchNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0009-0008-0098-7155 Eduard GallardoNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-3942-3436 Gemma Boera-CarniceroDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ilaria CallegariDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0003-3361-3084 Andrea CorteseDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-2208-5311 Emilien DelmontReferral Centre for Neuromuscular Diseases and ALS, La Timone Hospital, Marseille, France.ORCID 0000-0002-5591-2774 Claudia C GiannottaNeuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan University, Italy.
Eduardo Nobile-OrazioNeuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan University, Italy.ORCID 0000-0003-2624-8138 Romana HöftbergerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria.ORCID 0000-0002-5769-1100 Johann SellnerDepartment of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria; Affiliated with Karl Landsteiner University of Health Sciences, Krems, Austria.ORCID 0000-0001-8749-5533 Sarah Andrée Annie J HerdewynDepartment of Neurology and Neuromuscular Reference Center, Ghent University Hospital, Belgium.
Carvajal AlejandraDepartment of Neurology, Hospital Virgen de las Nieves, Granada, Spain.
Maarten J TitulaerDepartment of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-1033-3840 Bart C JacobsDepartment of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-8985-2458 Ruth HuizingaDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-9563-4860 Nicolau Ortiz CastellonDepartment of Neurology, Hospital Universitari Sant Joan, Reus, Spain.
Helena Pérez-PérezDepartment of Neurology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain.
Alicia Alonso-JiménezNeuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Belgium; and.
Jonathan De WinterNeuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Belgium; and.ORCID 0000-0002-0166-6758 Amaia JaureguiDepartment of Neurology, Hospital Universitario de Cruces, Barakaldo, Spain.
Oscar de la Calle-MartinDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-9717-053X Laura Martinez-MartinezDepartment of Immunology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0003-0126-158X Luis QuerolNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR Sant Pau, Barcelona, Spain.ORCID 0000-0002-4289-8264 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
BACKGROUND AND
objectivesThis study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).
methodsForty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the
resultsHLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, DISCUSSION: HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.
Indexed as
AutoantibodiesAutoimmune Diseases of the Nervous SystemContactin 1HLA-DRB1 ChainsAdultAgedFemaleGene FrequencyHumansMaleMiddle AgedAutoantibodiesCNTN1 protein, humanContactin 1HLA-DRB1 Chains
Identifiers
PMID42335443
PMCPMC13293632
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390